Norge - norsk - Statens legemiddelverk

ge healthcare ltd - krom (51cr) edetat - injeksjonsvæske, oppløsning - 3.7 mbq/ ml

Norge - norsk - Statens legemiddelverk

ge healthcare b.v. - natriumjodid (123i) - kapsel, hard

Norge - norsk - Statens legemiddelverk

ge healthcare b.v. - natriumjodid (123i) - injeksjonsvæske, oppløsning - 37 mbq/ ml

Norge - norsk - Statens legemiddelverk

ge healthcare buchler gmbh & co. kg - natriumjodid (131i) - kapsel, hard - 3.7 mbq

Norge - norsk - Statens legemiddelverk

ge healthcare buchler gmbh & co. kg - natriumjodid (131i) - injeksjonsvæske, oppløsning - 925 mbq/ ml

Norge - norsk - Statens legemiddelverk

ge healthcare buchler gmbh & co. kg - natriumjodid (131i) - injeksjonsvæske, oppløsning - 74 mbq/ ml

Den europeiske union - norsk - EMA (European Medicines Agency)

forte healthcare limited - fluoksetin - psychoanaleptics - hunder - som hjelpemiddel i behandlingen av separasjonsrelaterte forstyrrelser hos hunder manifestert av ødeleggelse og upassende oppførsel (vokalisering og upassende avføring og / eller vannlating) og kun i kombinasjon med adferdsmodifikasjonsteknikker.

Den europeiske union - norsk - EMA (European Medicines Agency)

mylan ire healthcare limited - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastiske midler - treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.

Den europeiske union - norsk - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastiske midler - vegzelma in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. vegzelma in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. for ytterligere informasjon om human epidermal growth factor receptor 2 (her2) status, se avsnitt 5. vegzelma in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with vegzelma in combination with capecitabine. for ytterligere informasjon om her2-status, se avsnitt 5. vegzelma, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (nsclc) other than predominantly squamous cell histology. vegzelma, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent nsclc with epidermal growth factor receptor (egfr) activating mutations (see section 5. vegzelma, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. vegzelma, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (vegf) inhibitors or vegf receptor–targeted agents. vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Den europeiske union - norsk - EMA (European Medicines Agency)

viatris healthcare limited - tobramycin - cystic fibrosis; respiratory tract infections - antibakterielle midler for systemisk bruk, - tobi podhaler er angitt for undertrykkende behandling av kroniske lunge infeksjoner forårsaket av pseudomonas aeruginosa i voksne og barn i alderen 6 år og eldre med cystisk fibrose. se avsnitt 4. 4 og 5. 1 om data i ulike aldersgrupper. det bør vurderes å offisielle retningslinjer for riktig bruk av antibakterielle midler.